Chimeric Antigen Receptor T Cell therapy

Reprogramming our T cell product candidates

An emergence of a new treatment

For many years, the cornerstones of cancer treatment have been surgery, chemotherapy and radiation therapy.

Recent years have seen the emergence of cancer immunotherapy, in which treatments harness the power of a patient’s immune system to combat their disease.

T cells are a type of white blood cell that form part of the immune system’s natural protection against cancer and infection. Normally our T cells can detect and eliminate abnormal or cancerous cells but sometimes these cells can escape detection and develop into tumors.

To overcome this problem Autolus is applying its advanced cell programming technologies and specialized manufacturing processes to develop programming T cell product candidates.

Latest Abstracts & Publications

See all
Nature Medicine
July 06 2023

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Molecular Therapy
March 21 2023

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

December 12 2022

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL (AUTO1/22)